Business Wire

Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile

NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC announced today that patients are being enrolled in a trial described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety ...
MarketWatch

Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), a clinical stage biotechnology company leading the development of specific NLRP3 inhibitors, presented preclinical data at ...
MarketWatch

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec's NLRP3 Inhibitor, Dapansutrile

NEW YORK, July 11, 2024 /PRNewswire/ -- Olatec Therapeutics, Inc. (Olatec), a leader in the emerging class of specific NLRP3 inhibitors, announced patients with type 2 diabetes mellitus (T2D) and ...